Today: 9 April 2026
Subscribe
Browse Category

NASDAQ:DYN 7 October 2025 - 4 January 2026

Biggest Stock Losers Today in the U.S. (Dec. 10, 2025): DYN, SLM, KTB, WAY and More Slide as Fed Decision Looms

Biggest Stock Losers Today in the U.S. (Dec. 10, 2025): DYN, SLM, KTB, WAY and More Slide as Fed Decision Looms

Dyne Therapeutics shares fell 16.9% to $18.44 after announcing a $300 million stock offering. SLM Corp dropped 15%, Kontoor Brands slid 9.5%, and Waystar Holding lost 8.4%. Major indexes were little changed as investors awaited the Federal Reserve’s interest-rate decision. The U.S. 10-year Treasury yield hovered near 4.19%.
10 December 2025
···········
Top US Stock Market Losers Today (December 9, 2025): HURA, Phreesia, Virgin Galactic, SLM, Gogo and More

Top US Stock Market Losers Today (December 9, 2025): HURA, Phreesia, Virgin Galactic, SLM, Gogo and More

TuHURA Biosciences plunged 36.9% after announcing a $15.6 million direct offering with warrants, triggering heavy dilution concerns. Phreesia, Euda Health, SLM Corp, Virgin Galactic, and Gogo each fell more than 15%. Major indexes stayed mostly flat, with the Dow up 0.2% and the S&P 500 up 0.1% as traders awaited the Federal Reserve’s policy decision.
9 December 2025
··········
Dyne Therapeutics Stock Soars on Duchenne Trial Data: What December 8 Means for DYN Investors

Dyne Therapeutics Stock Soars on Duchenne Trial Data: What December 8 Means for DYN Investors

Dyne Therapeutics shares jumped 14% to $23.20 by mid-afternoon Monday after the company reported its Phase 1/2 DELIVER trial in Duchenne muscular dystrophy met its primary endpoint. The stock touched an intraday high near $25.68 on volume over 2.5 million shares. Dyne plans to seek U.S. accelerated approval in 2026. The company reported $792 million in cash as of Q3 2025.
8 December 2025
·
Dyne Therapeutics Skyrockets on Breakthrough Data – Inside the Surge, Financials & 2026 Catalysts

Dyne Therapeutics Skyrockets on Breakthrough Data – Inside the Surge, Financials & 2026 Catalysts

Dyne Therapeutics shares jumped over 10% to around $14 after new trial data showed its lead therapy improved muscle function with no serious side effects. The stock is up about 75% in six months. Dyne’s Duchenne drug just received Orphan Drug status in Japan and positive analyst upgrades, with price targets averaging $34. The company ended June with $683.9 million in cash, extending its runway into 2027.
7 October 2025
·

Stock Market Today

  • Strattec Security (STRT) Rises 5.4% on Cost Savings, Shares Up Despite Mixed Earnings Outlook
    April 9, 2026, 5:05 AM EDT. Strattec Security (STRT) shares surged 5.4% to $80.4 on strong volume, recovering from a 3.8% decline over four weeks. The gain followed company announcements of cost-saving moves, including an early retirement program and restructuring in Mexico, forecasted to save $3.4 million annually. The firm reported a robust balance sheet with $99 million cash against only $2.5 million debt, enhancing financial flexibility. Despite expected quarterly earnings per share (EPS) of $1.14, down 24% year-on-year, and revenues sliding 2.4% to $140.7 million, the stock's consensus EPS estimates remained flat, weighing on further upside. Strattec holds a Zacks Rank #1 (Strong Buy), alongside Magna (MGA) in the automotive sector, which also gained 5.9%. Investors are advised to watch earnings revisions closely for directional cues.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 09.04.2026

9 April 2026
LIVEMarkets rolling coverageStarted: April 9, 2026, 12:00 AM EDTUpdated: April 9, 2026, 5:06 AM EDT Strattec Security (STRT) Rises 5.4% on Cost Savings, Shares Up Despite Mixed Earnings Outlook April 9, 2026, 5:05 AM EDT. Strattec Security (STRT) shares surged 5.4% to $80.4 on strong volume, recovering from a 3.8% decline over four weeks. The gain followed company announcements of cost-saving moves, including an early retirement program and restructuring in Mexico, forecasted to save $3.4 million annually. The firm reported a robust balance sheet with $99 million cash against only $2.5 million debt, enhancing financial flexibility. Despite expected quarterly earnings
Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

8 April 2026
IREN shares rose 1.8% to $35.74 Wednesday as investors assessed its $6 billion share program and shift from bitcoin mining to AI cloud services. The company’s revenue fell to $184.7 million last quarter, with a net loss of $155.4 million. IREN recently announced a five-year, $9.7 billion AI cloud deal with Microsoft. Options trading volume hit 103,000 contracts Tuesday, with sentiment described as mixed.
Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

8 April 2026
Amazon closed at $213.77 Tuesday, with BNP Paribas maintaining a $320 price target, citing strong AI demand despite Amazon’s planned $200 billion capex for 2026. The company’s February forecast of higher spending sent shares down 11.5% after hours, even as AWS revenue rose 24% to $35.6 billion in the December quarter. Alphabet and Microsoft are also ramping up AI infrastructure spending.
Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

8 April 2026
The Sensex surged 2,946 points to 77,562.90 on Wednesday, its best day in five years, as a U.S.-Iran ceasefire and steady RBI rates pushed Indian markets higher. Brent crude fell 14.4% to $93.49 a barrel, easing pressure on the rupee, which rose 0.5% to 92.58 per dollar. All 16 major sectors gained, led by financials and auto stocks. The RBI kept its repo rate at 5.25% and forecast slower growth ahead.
Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

8 April 2026
Stock Yards Bank & Trust Co. increased its Netflix stake by 1,141.9% to 29,074 shares in Q4, while Ethos Capital Management disclosed a new 19,610-share position worth $1.84 million. The moves come ahead of Netflix’s April 16 earnings report and follow a Goldman Sachs upgrade to Buy with a $120 target. Insiders Reed Hastings and Greg Peters sold shares earlier this year under preset trading plans. Netflix last traded at $98.82.
Go toTop